HIV Treatment and Prevention for Pregnant Women in West Africa
Author Information
Author(s): Tonwe-Gold Besigin, Ekouevi Didier K, Viho Ida, Amani-Bosse Clarisse, Toure Siaka, Coffie Patrick A, Rouet François, Becquet Renaud, Leroy Valériane, El-Sadr Wafaa M, Abrams Elaine J, Dabis François
Primary Institution: MTCT-Plus Programme, ACONDA, Abidjan, Côte d'Ivoire
Hypothesis
How effective is a two-tiered strategy of HIV treatment for pregnant women in preventing mother-to-child transmission in resource-limited settings?
Conclusion
The two-tiered strategy for preventing mother-to-child transmission of HIV is safe and highly effective in resource-constrained settings.
Supporting Evidence
- The rate of peripartum HIV transmission was 2.2%.
- The cumulative rate of infant HIV infection at 12 months was 5.7%.
- The overall probability of infant death or infection with HIV was 11.7% at 12 months.
Takeaway
This study shows that giving the right HIV treatment to pregnant women can help keep their babies safe from getting HIV.
Methodology
The study was an observational cohort study involving pregnant women receiving either HAART or short-course antiretroviral regimens based on their clinical status.
Potential Biases
Potential bias due to the observational nature of the study and the non-randomized assignment of treatment.
Limitations
The study had a relatively small sample size and was not designed to directly compare HAART to short-course treatments.
Participant Demographics
Median maternal age was 27 years, with a median CD4 T cell count of 338 cells/mm3.
Statistical Information
P-Value
p = 0.18
Confidence Interval
95% CI 0.3%–4.2%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website